Kindcare Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 07-01-2025
- Paid Up Capital ₹ 0.20 M
as on 07-01-2025
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.60 M
as on 07-01-2025
- Revenue 11.35%
(FY 2022)
- Profit 22.51%
(FY 2022)
- Ebitda -4.96%
(FY 2022)
- Net Worth 37.47%
(FY 2022)
- Total Assets 55.95%
(FY 2022)
About Kindcare Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹5.60 M.
Vineet Agarwal, Kavi Agarwal, and Ruchi Agarwal serve as directors at the Company.
- CIN/LLPIN
U51101DL2015PTC279004
- Company No.
279004
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Kindcare Drugs Private Limited offer?
Kindcare Drugs Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Digestive System Drugs & Medicines, Anti Ulcer Drugs, Anti Allergic Drug, Allergy Relief Tablets, Vitamin Tablets & Capsules, Methylcobalamin Tablets, Diabetes Medicine, Metformin Tablets.
Who are the key members and board of directors at Kindcare Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vineet Agarwal  | Director | 13-Apr-2015 | Current |
| Kavi Agarwal | Director | Current | |
| Ruchi Agarwal | Director | 01-Mar-2021 | Current |
Financial Performance of Kindcare Drugs.
Kindcare Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 11.35% increase. The company also saw a substantial improvement in profitability, with a 22.51% increase in profit. The company's net worth Soared by an impressive increase of 37.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kindcare Drugs?
In 2019, Kindcare Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kabia Medicare Private LimitedActive 3 years 7 monthsVineet Agarwal and Ruchi Agarwal are mutual person
Charges (Loans)
₹5.60 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.56 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Jul 2023 | Others | ₹5.60 M | Open |
How Many Employees Work at Kindcare Drugs?
Unlock and access historical data on people associated with Kindcare Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kindcare Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kindcare Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
